96 related articles for article (PubMed ID: 3663203)
1. Biological activity and mode of action of some dihydroorotic and dihydroazaorotic acid derivatives.
Miersch J; Grancharov K; Krauss GJ; Spassovska N; Karamanov G; Maneva L; Mladenova J; Golovinsky E
Biomed Biochim Acta; 1987; 46(5):307-15. PubMed ID: 3663203
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390).
Peters GJ; Sharma SL; Laurensse E; Pinedo HM
Invest New Drugs; 1987; 5(3):235-44. PubMed ID: 2822596
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar.
Cleaveland ES; Zaharevitz DW; Kelley JA; Paull K; Cooney DA; Ford H
Biochem Biophys Res Commun; 1996 Jun; 223(3):654-9. PubMed ID: 8687451
[TBL] [Abstract][Full Text] [Related]
4. The relation between inhibition of cell growth and of dihydroorotic acid dehydrogenase by brequinar sodium.
de Kant E; Pinedo HM; Laurensse E; Peters GJ
Cancer Lett; 1989 Jul; 46(2):123-7. PubMed ID: 2546667
[TBL] [Abstract][Full Text] [Related]
5. In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
Peters GJ; Schwartsmann G; Nadal JC; Laurensse EJ; van Groeningen CJ; van der Vijgh WJ; Pinedo HM
Cancer Res; 1990 Aug; 50(15):4644-9. PubMed ID: 2164443
[TBL] [Abstract][Full Text] [Related]
6. Differential susceptibility of dihydroorotate dehydrogenase/oxidase to Brequinar Sodium (NSC 368 390) in vitro.
Lakaschus G; Löffler M
Biochem Pharmacol; 1992 Mar; 43(5):1025-30. PubMed ID: 1313236
[TBL] [Abstract][Full Text] [Related]
7. Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer.
Peters GJ; Nadal JC; Laurensse EJ; de Kant E; Pinedo HM
Biochem Pharmacol; 1990 Jan; 39(1):135-44. PubMed ID: 2153375
[TBL] [Abstract][Full Text] [Related]
8. Elevated plasma dihydroorotate in Miller syndrome: Biochemical, diagnostic and clinical implications, and treatment with uridine.
Duley JA; Henman MG; Carpenter KH; Bamshad MJ; Marshall GA; Ooi CY; Wilcken B; Pinner JR
Mol Genet Metab; 2016 Sep; 119(1-2):83-90. PubMed ID: 27370710
[TBL] [Abstract][Full Text] [Related]
9. Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(12):666-678. PubMed ID: 30663496
[TBL] [Abstract][Full Text] [Related]
10. A sensitive, nonradiometric assay for dihydroorotic acid dehydrogenase using anion-exchange high-performance liquid chromatography.
Peters GJ; Laurensse E; Leyva A; Pinedo HM
Anal Biochem; 1987 Feb; 161(1):32-8. PubMed ID: 3578785
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors.
DeFrees SA; Sawick DP; Cunningham B; Heinstein PF; Morré DJ; Cassady JM
Biochem Pharmacol; 1988 Oct; 37(20):3807-16. PubMed ID: 2847745
[TBL] [Abstract][Full Text] [Related]
12. Redoxal as a new lead structure for dihydroorotate dehydrogenase inhibitors: a kinetic study of the inhibition mechanism.
Knecht W; Löffler M
FEBS Lett; 2000 Feb; 467(1):27-30. PubMed ID: 10664450
[TBL] [Abstract][Full Text] [Related]
13. Active site of dihydroorotate dehydrogenase A from Lactococcus lactis investigated by chemical modification and mutagenesis.
Björnberg O; Rowland P; Larsen S; Jensen KF
Biochemistry; 1997 Dec; 36(51):16197-205. PubMed ID: 9405053
[TBL] [Abstract][Full Text] [Related]
14. Insights into the mechanism of oxidation of dihydroorotate to orotate catalysed by human class 2 dihydroorotate dehydrogenase: a QM/MM free energy study.
Alves CN; Silva JR; Roitberg AE
Phys Chem Chem Phys; 2015 Jul; 17(27):17790-6. PubMed ID: 26087682
[TBL] [Abstract][Full Text] [Related]
15. Analogues of carbamyl aspartate as inhibitors of dihydroorotase: preparation of boronic acid transition-state analogues and a zinc chelator carbamylhomocysteine.
Kinder DH; Frank SK; Ames MM
J Med Chem; 1990 Feb; 33(2):819-23. PubMed ID: 1967653
[TBL] [Abstract][Full Text] [Related]
16. Dihydroorotate (dhout) and orotate (orout) utilizer mutants in yeast: identification of the dhout mutation and allelism of the DHO and URE2 genes.
Bloch JC; Pfeiffer P; Exinger F
C R Acad Sci III; 1998 Apr; 321(4):267-74. PubMed ID: 9766194
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of flavin reduction in class 2 dihydroorotate dehydrogenases.
Fagan RL; Nelson MN; Pagano PM; Palfey BA
Biochemistry; 2006 Dec; 45(50):14926-32. PubMed ID: 17154530
[TBL] [Abstract][Full Text] [Related]
18. Biological effects of the dihydroorotate dehydrogenase inhibitor polyporic acid, a toxic constituent of the mushroom Hapalopilus rutilans, in rats and humans.
Kraft J; Bauer S; Keilhoff G; Miersch J; Wend D; Riemann D; Hirschelmann R; Holzhausen HJ; Langner J
Arch Toxicol; 1998 Nov; 72(11):711-21. PubMed ID: 9879809
[TBL] [Abstract][Full Text] [Related]
19. 13C and 15N isotope effects for conversion of L-dihydroorotate to N-carbamyl-L-aspartate using dihydroorotase from hamster and Bacillus caldolyticus.
Anderson MA; Cleland WW; Huang DT; Chan C; Shojaei M; Christopherson RI
Biochemistry; 2006 Jun; 45(23):7132-9. PubMed ID: 16752903
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of brequinar sodium (Dup-785) against human head and neck squamous cell carcinoma xenografts.
Braakhuis BJ; van Dongen GA; Peters GJ; van Walsum M; Snow GB
Cancer Lett; 1990 Feb; 49(2):133-7. PubMed ID: 2306706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
